MSACL 2026 Abstract

Updates from C62 - the New Third Edition

Brian Rappold (1), William Clarke (2)
(1) Laboratory Corporation of America Holdings (2) John Hopkins University School of Medicine

Brian Rappold (Presenter) LabCorp

Relevant Financial Disclosures (within past 24 months, reported on Apr 27, 2026) Stock/Bonds Laboratory Corporation of America Holdings Salary Laboratory Corporation of America Holdings Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

Planned publication of a revision of C-62: Liquid Chromatography-Mass Spectrometry Methods by CLSI is set for August of 2026. The third edition of this document includes significant revisions and additions to the best practice guidance for LC-MS in the medical laboratory. This workshop will initiate discussion on the updates, providing attendees with up-to-date information and background on the new recommendations with members of the C62 document committee.

Take home pearls: Attendees will be given constructive information addressing the following features included in the C62-A3 revision:

1.) Updated performance metrics (Signal-to-noise/LoD/LoB/LLMI/ULMI).
2.) Clarification of LC-MS specific constraints to CLSI Evaluation Protocols (EP docs).
3.) Detailed Applications of Ion Ratios (e.g. different modes of acceptable range generation).
4.) Processes of verification of critical reagents.
5.) Quality controls for multiplexed analysis.